## Drug Summary
Kanamycin, known under various names including Efficin, Kanamytrex, and Winamycin, belongs to the aminoglycoside class of antibiotics. It is derived from the bacterium Streptomyces kanamyceticus and usually administered as kanamycin sulfate. Kanamycin is applicable in the treatment of a broad spectrum of infections primarily caused by aerobic, Gram-negative bacteria such as E. coli and Pseudomonas, as well as certain mycobacteria like those causing tuberculosis. Its pharmacodynamics involves binding to the 30S ribosomal subunit in bacteria, inhibiting protein synthesis which is crucial for bacterial growth. The drug is effective after intramuscular administration with rapid absorption, peaking within an hour. Kanamycin has minimal oral and topical absorption unless there is severe skin damage. It does not undergo significant metabolism.

## Drug Targets, Enzymes, Transporters, and Carriers
Kanamycin targets the 30S ribosomal protein S12 (rpsL) in bacteria, leading to misreading of mRNA and subsequent disruption of protein synthesis. Enzymatic mechanisms involving resistance to kanamycin include aminoglycoside 2'-N-acetyltransferase (aac) from Mycobacterium tuberculosis, kanamycin nucleotidyltransferase (knt) from Staphylococcus aureus, and aminoglycoside 3'-phosphotransferase (aphA1) from Escherichia coli. These enzymes mediate modifications that render the antibiotic ineffective against the bacterial cell. There are no specific transporters or carriers detailed for kanamycin, which suggests its action and transport might rely on passive processes or are yet to be fully understood.

## Pharmacogenetics
The pharmacogenetic profile of kanamycin primarily revolves around bacterial resistance mechanisms rather than human genetic variations. Resistance genes such as aac, knt, and aphA1 in pathogenic bacteria encode enzymes that modify the drug, leading to antibiotic resistance. There is no substantial evidence or detailed study linking human genetic variations to variations in response or adverse effects of kanamycin. However, due to the ototoxicity and nephrotoxicity associated with kanamycin, genetic predispositions affecting renal or auditory function could potentially influence the drug's toxicity profile in patients. Further research might be necessary to establish concrete pharmacogenetic relationships involving human gene variants.